MXPA03001142A - Metodo y composicion para alterar una patologia mediada por celulas t. - Google Patents
Metodo y composicion para alterar una patologia mediada por celulas t.Info
- Publication number
- MXPA03001142A MXPA03001142A MXPA03001142A MXPA03001142A MXPA03001142A MX PA03001142 A MXPA03001142 A MX PA03001142A MX PA03001142 A MXPA03001142 A MX PA03001142A MX PA03001142 A MXPA03001142 A MX PA03001142A MX PA03001142 A MXPA03001142 A MX PA03001142A
- Authority
- MX
- Mexico
- Prior art keywords
- cell mediated
- mediated pathology
- patient
- chimeric proteins
- altering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invencion proporciona un metodo para alterar una patologia mediada por celulas T en un paciente. Este metodo comprende administrar una composicion que comprende al menos una y/o dos proteinas quimericas. Cada proteina quimerica comprende al menos una porcion de la region Va o V?? de un TCR de celulas T particulares de un paciente que tiene una patologia mediada por celulas T, y una region constante de inmunoglobulina. Los genes que codifican para las regiones Va y/o V?? y los genes que codifican para regiones constantes de inmunoglobulina se aislan e insertan en un vector de expresion. Las proteinas quimericas se producen al introducir los vectores de expresion en lineas de celulas de insecto. Las proteinas quimericas se purifican usando columnas de afinidad de anticuerpos, y luego se conjugan quimicamente a un vehiculo inmunogenico, hemocianina de lapa en forma de cerradura (KLH). Ya que los conjugados comprenden proteinas quimericas hechas especificamente de celulas T particulares de un paciente que tiene una patologia mediada por celulas T, cuando se administran a tal paciente, con o sin una citocina, tal como CSF de granulocitos-macrofagos, o una quimiocina, pueden inducir respuestas inmunes para alterar la patologia mediada por celulas T.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22472300P | 2000-08-11 | 2000-08-11 | |
US22472200P | 2000-08-11 | 2000-08-11 | |
US26613301P | 2001-02-01 | 2001-02-01 | |
PCT/US2001/025203 WO2002013861A2 (en) | 2000-08-11 | 2001-08-10 | Method and composition for altering a t cell mediated pathology |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03001142A true MXPA03001142A (es) | 2004-08-02 |
Family
ID=27397392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03001142A MXPA03001142A (es) | 2000-08-11 | 2001-08-10 | Metodo y composicion para alterar una patologia mediada por celulas t. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20030012782A1 (es) |
EP (1) | EP1309373A2 (es) |
JP (1) | JP2004506021A (es) |
KR (1) | KR20030064377A (es) |
AU (2) | AU8330401A (es) |
CA (1) | CA2416794A1 (es) |
HK (1) | HK1052314A1 (es) |
MX (1) | MXPA03001142A (es) |
SG (1) | SG143058A1 (es) |
WO (1) | WO2002013861A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101130597B1 (ko) | 2005-09-13 | 2012-04-02 | 다카라 바이오 가부시키가이샤 | T 세포 리셉터 및 그 리셉터를 코드하는 핵산 |
GB0721686D0 (en) * | 2007-11-05 | 2007-12-12 | Medinnova As | Polypeptides |
WO2015058780A1 (en) * | 2013-10-25 | 2015-04-30 | Biontech Ag | Method and kit for determining whether a subject shows an immune response |
JP7012364B2 (ja) * | 2016-08-05 | 2022-02-14 | 国立大学法人東北大学 | T細胞受容体の認識機構を用いたがん又は感染症の治療及び診断 |
EP3747456A4 (en) * | 2018-01-31 | 2021-12-01 | Tohoku University | PROCESS FOR REGULATING THE EXPRESSION OF THE SPECIFIC MHC OF AN ANTIGEN |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US631690A (en) * | 1898-11-14 | 1899-08-22 | Joseph Franklin | Polishing or abrading device. |
CA1023287A (en) * | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4468464A (en) * | 1974-11-04 | 1984-08-28 | The Board Of Trustees Of The Leland Stanford Junior University | Biologically functional molecular chimeras |
US4195128A (en) * | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) * | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) * | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4704362A (en) * | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4229537A (en) * | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4338397A (en) * | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
IT1136411B (it) * | 1980-06-17 | 1986-08-27 | Oddo Borghetto | Complesso di elementi distanziatori e allineatori per blocchetti particolarmente adatti per pareti o pannelli in vetro cemento |
US4661586A (en) * | 1981-11-17 | 1987-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Monoclonal anti-idiotype antibodies |
US4816249A (en) * | 1981-11-17 | 1989-03-28 | The Board Of Trustees Of The Leland Stanford Junior University | Monoclonal anti-idiotype antibodies |
US4444878A (en) * | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US4512922A (en) * | 1982-12-22 | 1985-04-23 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4745051A (en) * | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
US4840896A (en) * | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
US5053224A (en) * | 1983-11-07 | 1991-10-01 | Hilary Koprowski | Induction of antibody response to solid tumors with anti-idiotype antibodies |
AU594014B2 (en) * | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
US5908763A (en) * | 1984-07-06 | 1999-06-01 | Novartis Corporation | DNA encoding GM-CSF and a method of producing GM-CSF protein |
UA29377C2 (uk) * | 1984-09-19 | 2000-11-15 | Новартіс Аг | Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів |
US5391485A (en) * | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
US5078996A (en) * | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
GB8601597D0 (en) * | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5162111A (en) * | 1986-07-30 | 1992-11-10 | Grabstein Kenneth H | Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor |
US5580561A (en) * | 1987-03-06 | 1996-12-03 | Cercek; Boris | Methods and pharmaceutical compositions for blocking suppression of immune defense mechanisms using an antibody, a factor, or an antisense peptide |
JPH01193227A (ja) * | 1988-01-29 | 1989-08-03 | Res Dev Corp Of Japan | 癌免疫療法補助剤 |
US5227159A (en) * | 1989-01-31 | 1993-07-13 | Miller Richard A | Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies |
US5861164A (en) * | 1989-03-21 | 1999-01-19 | The Immune Response Corporation | Vaccination against diseases resulting from pathogenic responses by specific T cell populations |
US5612035A (en) * | 1989-03-21 | 1997-03-18 | The Immune Response Corporation | Vaccination against diseases resulting from pathogenic responses by specific T cell populations |
EP0482068A1 (en) * | 1989-07-14 | 1992-04-29 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
US5281699A (en) * | 1990-06-01 | 1994-01-25 | Tanox Biosystems, Inc. | Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins |
US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
US5370901A (en) * | 1991-02-15 | 1994-12-06 | Bracco International B.V. | Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients |
US5904920A (en) * | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
CA2139756A1 (en) * | 1992-07-08 | 1994-01-20 | Eric M. Bonnem | Use of gm-csf as a vaccine adjuvant |
WO1994008601A1 (en) * | 1992-10-14 | 1994-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates |
US5679347A (en) * | 1992-12-10 | 1997-10-21 | Brigham And Women's Hospital | Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods |
US5728377A (en) * | 1993-07-20 | 1998-03-17 | Board Of Regents, The University Of Texas System | Methods and compositions incorporating IP-10 |
IL110787A0 (en) * | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
US6348449B1 (en) * | 1993-09-21 | 2002-02-19 | The Trustees Of The University Of Pennsylvania | Methods of inducing mucosal immunity |
DE4406172C2 (de) * | 1994-02-25 | 2003-10-02 | Sanol Arznei Schwarz Gmbh | Polyester |
US5478556A (en) * | 1994-02-28 | 1995-12-26 | Elliott; Robert L. | Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor |
AUPM543894A0 (en) * | 1994-05-04 | 1994-05-26 | Commonwealth Scientific And Industrial Research Organisation | An adjuvant |
FR2724182B1 (fr) * | 1994-09-02 | 1996-12-13 | Pasteur Institut | Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations |
US5789206A (en) * | 1995-07-07 | 1998-08-04 | Myriad Genetics, Inc. | Method for ligating adaptors to nucleic acids which methods are useful for obtaining the ends of genes |
US5900238A (en) * | 1995-07-27 | 1999-05-04 | Immunex Corporation | Vaccine delivery system |
US5942253A (en) * | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
US6083703A (en) * | 1996-02-09 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes |
US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
US6096313A (en) * | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
US6312718B1 (en) * | 1996-02-16 | 2001-11-06 | Biomira Usa, Inc. | Vaccine for B-cell malignancies |
US5776746A (en) * | 1996-05-01 | 1998-07-07 | Genitope Corporation | Gene amplification methods |
CA2264966A1 (en) * | 1996-09-11 | 1998-03-19 | The General Hospital Corporation | Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein |
WO1998012311A2 (en) * | 1996-09-11 | 1998-03-26 | The General Hospital Corporation | Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
US6063905A (en) * | 1997-01-07 | 2000-05-16 | Board Of Regents, The University Of Texas System | Recombinant human IGA-J. chain dimer |
US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
AU9018598A (en) * | 1997-08-13 | 1999-03-08 | Fox Chase Cancer Center | Prognostic compositions for prostate cancer and methods of use thereof |
KR100712256B1 (ko) * | 1997-10-02 | 2007-04-27 | 알토 바이오사이언스 코포레이션 | 가용성 단일쇄 t-세포 수용체 단백질 |
US6309632B1 (en) * | 1998-04-28 | 2001-10-30 | Immunex Corporation | Methods for treating HIV-infected patients by administering GM-CSF |
IL127142A0 (en) * | 1998-11-19 | 1999-09-22 | Yeda Res & Dev | Immune cells having predefined biological specificity |
US6342216B1 (en) * | 1999-03-17 | 2002-01-29 | The Board Of Regents, The University Of Texas System | Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
AU2001275246B2 (en) * | 2000-06-05 | 2006-06-29 | Altor Bioscience Corporation | T cell receptor fusions and conjugates and methods of use thereof |
-
2001
- 2001-08-10 EP EP01962096A patent/EP1309373A2/en not_active Withdrawn
- 2001-08-10 JP JP2002519000A patent/JP2004506021A/ja active Pending
- 2001-08-10 AU AU8330401A patent/AU8330401A/xx active Pending
- 2001-08-10 CA CA002416794A patent/CA2416794A1/en not_active Abandoned
- 2001-08-10 KR KR10-2003-7001908A patent/KR20030064377A/ko not_active Application Discontinuation
- 2001-08-10 AU AU2001283304A patent/AU2001283304B2/en not_active Ceased
- 2001-08-10 SG SG200501236-4A patent/SG143058A1/en unknown
- 2001-08-10 MX MXPA03001142A patent/MXPA03001142A/es not_active Application Discontinuation
- 2001-08-10 US US09/927,122 patent/US20030012782A1/en not_active Abandoned
- 2001-08-10 WO PCT/US2001/025203 patent/WO2002013861A2/en active IP Right Grant
-
2003
- 2003-06-21 HK HK03104475.3A patent/HK1052314A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP1309373A2 (en) | 2003-05-14 |
AU2001283304B2 (en) | 2005-05-05 |
HK1052314A1 (zh) | 2003-09-11 |
AU8330401A (en) | 2002-02-25 |
CA2416794A1 (en) | 2002-02-21 |
WO2002013861A3 (en) | 2002-12-05 |
JP2004506021A (ja) | 2004-02-26 |
WO2002013861A2 (en) | 2002-02-21 |
US20030012782A1 (en) | 2003-01-16 |
KR20030064377A (ko) | 2003-07-31 |
SG143058A1 (en) | 2008-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102977213B (zh) | 抗nkg2a 的单克隆抗体 | |
RU2432357C2 (ru) | ПОЛИПЕПТИДЫ НЕТИПИРУЕМОЙ Haemophilus influenzae | |
CO4850562A1 (es) | Proceso para producir una preparacion concentrada de anticuerpos | |
OA07388A (fr) | Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués. | |
MX9800684A (es) | Formulacion de proteinas liofilizadas isotonicas estables. | |
UA87093C2 (ru) | ГУМАНИЗИРОВАННЫЙ ИММУНОГЛОБУЛИН, КОТОРЫЙ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Аβ) | |
IL150571A0 (en) | Novel chimeric proteins and methods for using the same | |
AU1955088A (en) | Avirulent microbes, incapable of producing functional adenylate cyclase and cyclic AMP | |
SG128482A1 (en) | Method and composition for altering a b cell mediated pathology | |
NO940736L (no) | DNA sekvenser som koder for gelonin polypeptid | |
DE69529822D1 (de) | Interleukin-15-rezeptoren | |
DK1119630T3 (da) | Nukleinsyrekonstruktioner til genetisk immunisering | |
MXPA03001142A (es) | Metodo y composicion para alterar una patologia mediada por celulas t. | |
WO1999013907A3 (en) | Methods to improve immunogenicity of antigens and specificity of antibodies | |
WO1996018646A3 (en) | Heat shock protein peptides and methods for modulating autoimmune central nervous system disease | |
Hacker et al. | Formation of an Antibody with Serologic Specificity for N6-(Δ2-Isopentenyl) Adenosine | |
EP0369816A3 (en) | Monoclonal antibodies specific for human polymorphic epithelial mucin | |
FR2692282B1 (fr) | Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications. | |
WO2001057219A3 (en) | Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods | |
BG99074A (en) | Recombinant human hiv neutralizing monoclonal antibodies for prophylaxy and treatment of hiv infection | |
NZ500151A (en) | A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence | |
Srebreva et al. | Specificity studies on anti‐histone H1 antibodies obtained by different immunization methods | |
PT866861E (pt) | Clonagem molecular e caracterizacao de moleculas relacionadas com relaxina e com a familia dos ligandos da insulina | |
DE3853383D1 (de) | Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit. | |
CoIco et al. | Exposure to crosslinked IgD induces receptors for IgD on T cells in vivo and in vitro. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |